Reversal of Olfactory Disturbance in Allergic Rhinitis Related to OMP Suppression by Intranasal Budesonide Treatment

Jung, Ah Yeoun; Kim, Young Hyo

doi:10.4168/aair.2020.12.1.110

Cited by 9 publications

(11 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Asthma and olfactory impairment have never been linked, according to a recent report published in 2021 by Rhyou et al 48 However, the presence of allergic rhinitis or sinusitis in association with asthma surely decreases the olfactory sensation. 29 , 49 …”

Section: Discussionmentioning

confidence: 99%

Impact of Systemic Diseases on Olfactory Function in COVID-19 Infected Patients

Awwad¹,

Elhay²,

Rabie³

et al. 2022

IJGM

View full text Add to dashboard Cite

Background COVID-19 (SARS-CoV-2/2019-nCoV) is now a major public health threat to the world. Olfactory dysfunctions (ODs) are considered potential indicating symptoms and early case identification triaging for coronavirus disease 2019 (COVID-19). The most common reported comorbidities are diabetes mellitus, chronic lung disease, and cardiovascular disease. The objective of this study was to evaluate prevalence of different types of smell disorders in patients with laboratory-confirmed COVID-19 infection and impact of involved systemic diseases. Methodology A cross-sectional retrospective study has been done for patients with laboratory-confirmed COVID-19 infection (mild-to-moderate). The data collected from patient’s files and developed online electronic questionnaire (WhatsApp) based on the patients most common and recurrent reported data including: a) symptoms of olfactory dysfunction and associated covid19 symptoms fever and headache, cough, sore throat, pneumonia, nausea, vomiting and diarrhea, arthralgia and myalgia and taste dysfunction. b) Associated systemic diseases including: diabetes, hypertension, asthma, chronic renal disease, chorionic liver disease and hypothyroidism. Results Of 308 patients confirmed with Covid-19 infection, (72.4%) developed OD distributed as follows; complete anosmia (57.8%), troposmia (8.4%), hyposmia (2.9%), partial anosmia (2.6%) and euosmia (0.6%). Significantly increased prevalence of diabetes, hypertension asthma in the group with olfactory dysfunction (p < 0.001), chronic liver disease (p = 0.005), and hypothyroidism (p = 0.03). Conclusion The development of ODs after Covid-19 infection was associated with mild disease form and lower hospitalization. In addition, it showed significant relationship with preexisting systemic diseases. Anosmia is the common modality of ODs.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of Systemic Diseases on Olfactory Function in COVID-19 Infected Patients

Awwad¹,

Elhay²,

Rabie³

et al. 2022

IJGM

View full text Add to dashboard Cite

show abstract

“…Therefore, precautions should be taken when using steroids in such situations to avoid complications associated with this therapy such as immunosuppression. Using steroids intranasally is helpful in reducing the exacerbation of viral infection in the upper respiratory tract, olfactory dysfunction, and epithelial damage with less complication (Stenner et al 2008 ; Jung and Kim 2020 ). Another strategy of the therapy is the administration of nasal saline irrigations containing drugs that act by competitive inhibition of ACE2 receptor (Wong et al 2004 ), followed by nasal and oral corticosteroids (Lechien et al 2020a , b , c ).…”

Section: Management and Treatment Options Of Covid-19 Anosmiamentioning

confidence: 99%

“Anosmia” the mysterious collateral damage of COVID-19

et al. 2022

View full text Add to dashboard Cite

COVID-19 pandemic spreads worldwide, with more than 100 million positive cases and more than 2 million deaths. From the beginning of the COVID-19 pandemic, several otolaryngologists described many cases of a sudden loss of smell (anosmia) associated with the disease with or without additional symptoms. Anosmia is often the first and sometimes the only sign in the asymptomatic carriers of COVID-19. Still, this disorder is underestimated, and it is not life-threatening. However, it significantly decreases the quality of life. This olfactory dysfunction continues in several cases even after the nasopharyngeal swab was negative. The occurrence of anosmia can be used as a screening tool for COVID-19 patients and can be used to identify these patients to accomplish the isolation and tracking procedures. In this review, we highlighted the possible mechanisms of anosmia in COVID-19 patients, major pathologies and features of anosmia, implications of anosmia in early diagnosis of COVID-19, evaluation of the smell function during COVID-19, and management and treatment options of COVID-19 anosmia.

show abstract

“…4,19 Several underlying etiological conditions cause olfactory dysfunctions, in which CRS (or AR) is the main cause of olfactory loss due to sinonasal diseases. [21][22][23] To date, there is no evidence of an association between asthma and olfactory dysfunction. Upper airway diseases such as CRS and rhinitis are commonly accompanied by asthma; therefore, we deduced that there would be a high prevalence of olfactory dysfunction in patients with asthma and a substantial association between these conditions.…”

Section: Dovepressmentioning

confidence: 99%

Association Between Olfactory Function and Asthma in Adults

Rhyou

Bae

Nam

2021

JAA

View full text Add to dashboard Cite

Purpose: Chronic rhinosinusitis (CRS) and allergic rhinitis (AR) are common asthmaassociated upper airway diseases. Olfactory dysfunction, a common symptom among these patients, is an increasingly recognized condition that is associated with a reduced quality of life and major health outcomes. However, there are few studies on the association between olfactory function and asthma. We investigated the relationship between asthma and olfactory function. Patients and Methods: A total of 146 patients with asthma aged >18 years were retrospectively analyzed from August 2019 to February 2020. Olfactory function was assessed using the Sniffin' stick test or the YSK olfactory function test. We compared the clinical parameters of patients with olfactory dysfunction and patients with normosmia. Results: Of the total participants, 68 (46.6%) showed olfactory dysfunction (hyposmia, n=31; anosmia, n=37). The patients with olfactory dysfunction were older, had longer durations of asthma, and a higher proportion of those with poor general health, CRS, and nasal polyps compared to patients with normosmia. However, there were no significant differences in the socioeconomic status, lung function, asthma severity, and use of inhaled corticosteroids or intranasal steroids between the two groups. Age (odds ratio: 1.044, 95% confidence interval: 1.009-1.081, P=0.012), poor general health (3.304, P=0.018), CRS (2.589, P=0.021), and nasal polyps (3.306, 1.1-9.94, P=0.033) were significantly associated with olfactory dysfunction. Conclusion: Olfactory dysfunction was quite frequently observed in adults with asthma. Age, poor general health, CRS, and nasal polyps were significantly associated with olfactory dysfunction.

show abstract

Reversal of Olfactory Disturbance in Allergic Rhinitis Related to OMP Suppression by Intranasal Budesonide Treatment

Cited by 9 publications

References 29 publications

Impact of Systemic Diseases on Olfactory Function in COVID-19 Infected Patients

Impact of Systemic Diseases on Olfactory Function in COVID-19 Infected Patients

“Anosmia” the mysterious collateral damage of COVID-19

Association Between Olfactory Function and Asthma in Adults

Contact Info

Product

Resources

About